Cite
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
MLA
Vassal, G., et al. “Prospective Validation of a Novel IV Busulfan Fixed Dosing for Paediatric Patients to Improve Therapeutic AUC Targeting without Drug Monitoring.” Cancer Chemotherapy & Pharmacology, vol. 61, no. 1, Jan. 2008, pp. 113–23. EBSCOhost, https://doi.org/10.1007/s00280-007-0455-2.
APA
Vassal, G., Michel, G., Espérou, H., Gentet, J. C., Valteau-Couanet, D., Doz, F., Mechinaud, F., Galambrun, C., Neven, B., Zouabi, H., Nguyen, L., & Puozzo, C. (2008). Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemotherapy & Pharmacology, 61(1), 113–123. https://doi.org/10.1007/s00280-007-0455-2
Chicago
Vassal, G., G. Michel, H. Espérou, J. C. Gentet, D. Valteau-Couanet, F. Doz, F. Mechinaud, et al. 2008. “Prospective Validation of a Novel IV Busulfan Fixed Dosing for Paediatric Patients to Improve Therapeutic AUC Targeting without Drug Monitoring.” Cancer Chemotherapy & Pharmacology 61 (1): 113–23. doi:10.1007/s00280-007-0455-2.